Statera Biopharma, Inc. entered a Binding Memorandum of Understanding to acquire 25% in Holobeam Technologies, Inc. for $25 million on October 12, 2022. The consideration will be paid via the issuance of the Company's preferred stock or a combination of preferred stock and cash. The Transaction is subject to availability of at least $10 million on the balance sheet of the Statera Biopharma at the close of the Transaction, approval by a majority of HOLO's stockholders and approval by board of directors of Statera Biopharma, receipt of a fairness opinion by HOLO from an investment bank of its choosing and other customary conditions.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0007 USD | 0.00% | 0.00% | +16.67% |
2023 | Statera Biopharma, Inc. entered into a letter of intent to acquire Worksite Labs. | CI |
2023 | Statera Biopharma, Inc.(OTCPK:STAB) dropped from S&P TMI Index | CI |
1st Jan change | Capi. | |
---|---|---|
+16.67% | 50.81K | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- STAB Stock
- News Statera Biopharma, Inc.
- Statera Biopharma, Inc. entered a Binding Memorandum of Understanding to acquire 25% in Holobeam Technologies, Inc. for $25 million.